(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 April 2008 (17.04.2008)

PCT

(10) International Publication Number
WO 2008/045170 A2

(51) International Patent Classification:
A61K 31/401 (2006.01) *A61K 31/22* (2006.01)
A61K 31/366 (2006.01) *A61K 31/202* (2006.01)

(21) International Application Number:
PCT/US2007/019539

(22) International Filing Date:
7 September 2007 (07.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/850,280 10 October 2006 (10.10.2006) US
11/742,292 30 April 2007 (30.04.2007) US

(71) Applicant *(for all designated States except US)*: **RELIANT PHARMACEUTICALS, INC.** [US/US]; 110 Allen Road, Liberty Corner, NJ 07938 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **RONGEN, Roelof, M. L.** [NL/US]; 131 Fairmont Road East, Caliton, NJ 07830 (US). **SHALWITZ, Robert, A.** [US/US]; 2549 Bryden Rd., Bexley, OH 43209 (US). **KLING, Douglas** [US/US]; 73 Alloway Road, Parsippany, NJ 07054 (US). **DOYLE, Ralph, T., Jr** [US/US]; 7 Berkshire Way, Milford, NJ 08848 (US).

(74) Agents: **BERMAN, Richard, J.** et al.; Arent Fox Kintner Plotkin & Kahn, PLLC, Suite 600, 1050 Connecticut Avenue, N.W., Washington, DC 20036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

WO 2008/045170 A2

(54) Title: STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCTION OF APO-B LEVELS

(57) Abstract: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of- patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.